Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005
- 204 Downloads
The purpose of this study was to examine recent trends in the prescribing of hormone therapy for menopause, tibolone, and bisphosphonate preparations for the prevention or treatment of osteoporosis, in the UK in relation to publication of research evidence on the health effects of hormone therapy and subsequent changes in prescribing advice.
Individual patient-level data were obtained on the prescribing of hormone therapy, tibolone, and bisphosphonates by general practitioners in the UK between 1991 and 2005 to women aged 40 years and older in the UK General Practice Research Database. Overall and age-specific prescribing prevalence were calculated for each therapy type. Prescribing prevalence was also calculated for subcategories of hormone therapy and bisphosphonates.
Prescribing of hormone therapy to women aged 40 years and older increased between 1991 and 1996 and remained fairly stable between 1997 and 2001. Hormone therapy prescribing has fallen by about 50% since 2002. Tibolone, a selective tissue estrogenic activity regulator, is prescribed much less commonly than hormone therapy but shows a similar pattern. Prescribing of bisphosphonates increased rapidly throughout the study period, particularly in women aged 70 years and older, with the pattern of prescribing reflecting to some extent, the availability of new weekly formulations.
Trends in the prescribing of hormone therapy in the UK appear to closely reflect new epidemiological evidence and prescribing advice. It is likely that the substantial fall in hormone therapy and tibolone prescribing seen since 2002 is a direct consequence of the publication of Women’s Health Initiative trial results and subsequent changes in advice given by the Committee on Safety of Medicines. The 1997 publication of results from the Collaborative Group on Hormonal Factors in Breast Cancer and 2003 publication of the Million Women Study findings may also have impacted on trends, particularly within certain age groups. The substantial and continuing increase in prescribing prevalence of bisphosphonates reinforces the need for research into the long-term risks and benefits of these therapies.
KeywordsHormone therapy Bisphosphonates Prescribing Tibolone GPRD
- 3.Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059CrossRefGoogle Scholar
- 5.Medicines Control Agency (MCA)/Committee on Safety of Medicines (2002) ‘New product information for hormone replacement therapy’. Current Problems in Phamacovigilance, vol 28, April, 1–2Google Scholar
- 11.Medicines and Healthcare products Regulatory Agency (MHRA)/Committee on Safety of Medicines (2004) ‘Review of the evidence on long-term safety of HRT’. Current Problems in Phamacovigilance, vol 30, October, 4–6Google Scholar
- 12.General Practice Research Database (GPRD) (20/04/06) http://www.gprd.com
- 13.Joint Formulary Committee (2005) British National Formulary 50 ed. British Medical Association and Royal Pharmaceutical Society of Great Britain: LondonGoogle Scholar
- 26.Medicines Control Agency/Committee on Safety of Medicines (1998) ‘Reminder: severe oesophageal reactions with alendronate sodium (Fosamax)’. Current Problems in Phamacovigilance, vol 24, August, 13Google Scholar